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Proteolysis-Induced Pathomechanisms 
in Acute Inflammation and 
Related Therapeutic Approaches 
M . JOCHUM 1 , W . MACHLEIDT2 , and H . FRITZ1 
1 Introduction 
1.1 Aspects of Proteolytic Pathomechanisms i n I n f l a m m a t i o n 
Proteolysis-induced pathomechanisms seem to play a major role in the primary re-
sponse of the organism to inflammatory Stimuli such as tissue destruction due to mul-
tiple trauma and major surgery or invasive microbes and endotoxins in sepsis. Phy-
siologically, the inflammation response is directed towards inactivating and elimi-
nating the deleterious agents and to initiate the process of repair and healing. Yet, the 
activation of the complex interacting cellular and humoral defence mechanisms nec-
essary for this purpose carries with it also the risk of damaging healthy tissue, thus 
perpetuating the inflammatory process. In this respect, the lysosomal serine Pro-
teinase elastase and the cysteine Proteinase cathepsin B of the primary inflammatory 
cells, polymorphonuclear (PMN) granulocytes, and monocytes/macrophages are sup-
posed to be potent effectors of proteolytic tissue damage if they are discharged extra-
cellularly in high amounts during activation of the phagocytes. Moreover, proteinases 
of humoral origin (plasma kallikrein, thrombin, plasmin, complement esterases) and 
protein split products generated by their proteolytic action (fibrinopeptides and fibrin 
monomers, fibronectin peptides, complement-derived factors such as C3a, C4a, and 
C5a, etc.) have been proven to be of major importance as strong stimulators of the 
primary defence cells. 
In addition to lysosomal proteinases, highly reactive oxygen species produced by 
the respiratory burst are also extracellularly liberated during phagocytosis. By this 
means, vital structural elements (basal membranes, cell receptors, fibronectin, elastin, 
collagens, proteoglycans, etc.) as well as humoral factors including plasma proteins in 
close vicinity to the phagocytizing cells may be impaired unless the lysosomal prote-
olytic enzymes and oxidants are inactivated by their physiological regulators, the 
Proteinase inhibitors (aj-Proteinase inhibitor, a2-macroglobulin, cysteine Proteinase 
inhibitors) and antioxidants (Superoxide dismutase, catalase, glutathione redox Sy-
stem, ceruloplasmin). 
Yet, due to an overstressed phagocytic activity of PMN granulocytes and mono-
cytes/macrophages during severe inflammation, the main antagonist of PMN elastase, 
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Fig. 1. Schematic depiction of humoral and cellular proteolytic pathomechanisms involved in 
the development of multiple organ failure (MOF). Destructive proteases (elastase, cathepsin B) 
and other cell constituents are released after activation of the phagocytes by blood cascade 
proteinases (plasma kallikrein, factor Xlla, thrombin, etc.) and Polypeptides (fibrinogen and fi-
bronectin split products, complement factors C3a, C4a, and C5a, etc.). For detailled explana-
tion, see text 
the a rproteinase inhibitor (c^PI), is highly susceptible not only to proteolytic cleav-
age by cysteine and metallo proteinases released from the mononuclear cells, but also 
to oxidative denaturation of the reactive inhibitory site in the molecule. This enables 
an unrestricted local digestive activity by PMN elastase combined also with fatal con-
sequences for the hemostasis System. As shown by several authors, PMN elastase can 
easily degrade and inactivate the principal inhibitors (antithrombin III, a^plasmin in-
hibitor, Cl-inactivator) of proteinases of the blood cascade Systems (clotting, fibrino-
lysis, complement), thus allowing the maintenance of life-threatening consumption of 
hemostasis factors and the additional production of potent stimulators of the phago-
cytes as mentioned above. Moreover, the proteolytic inactivation of the plasma in-
hibitors may be greatly enhanced by their oxidative denaturation in the surroundings 
of phagocytizing cells. 
The interrelationship of cellular and humoral proteolytic pathomechanisms even-
tually contributing to the development of multiple organ failure (MOF) in the course 
of severe acute inflammation is depicted in a simplified version in Fig. 1. A compre-
hensive review of literature on this topic is given by Jochum (1988), Jochum and Fritz 
(1989), Assfalg-Machleidt et al. (1990), and Jochum and Fritz (1990). 
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1.2 R a t i o n a l e for Therapeutic Use of Proteinase I n h i b i t o r s 
To obtain fundamental information about the extent proteases may participate in the 
initiation and perpetuation of inflammatory processes, the following indications - as a 
modification of the Koch-Dale criteria - have to be proven in clinical and/or experi-
mental studies: 
1. The release of the lysosomal proteinases (e. g., PMN elastase, cathepsin B) and the 
activation of proteolytic blood cascade enzymes have to be verified in correlation 
to the severity of the inflammation. 
2. The consumption of Proteinase inhibitors and other plasma factors susceptible to 
proteolytic degradation should coincide with the occurrence of proteolytic activ-
ity. 
3. Specific split products of functional proteins generated by the proteolytic action of 
lysosomal proteinases have to be shown in correlation to the extracellular release 
of these enzymes. 
4. The use of specific exogenous Proteinase inhibitors as therapeutic tools should 
prevent or at least reduce to some extent severe signs of inflammation. 
In the following, characteristic results obtained from several clinical and experimental 
studies dealing with multiple trauma and/or septicemia are given. They demonstrate 
clearly the involvement of proteolysis-induced pathomechanisms in acute inflamma-
tion necessitating Proteinase inhibition as a convenient therapeutic approach. 
2 Methodology 
Serially drawn citrated plasma, bronchoalveolar lavage fluid (BALF), and Peritonitis 
exudate samples were used to quantify proteinases, inhibitors, and plasma protein 
split products. 
Measurements of the lysosomal serine Proteinase PMN elastase were carried out 
with a commercially available, highly specific two-site sandwich enzyme immunoas-
say kit (E. Merck, Darmstadt, Germany), which detects elastase only as an inactive 
complex with (XjPI (Neumann and Jochum 1984). Since, in contrast to plasma, BALF 
and Peritonitis exudate samples may contain proteolytically active elastase in addition 
to the complex, parts of these specimens were incubated also with a surplus of otjPI in 
vitro and reassayed for an increase in elastase-ctjPI complex as a measure of enzy-
matic elastase activity in vivo. The cysteine Proteinase cathepsin B activity was quan-
tified using a fluorometric assay as described by Assfalg-Machleidt et al. (1988). Ca-
seinolytic activity of local body fluids due to elastase and/or cathepsin B was detected 
using resorufin-labeled casein (Boehringer, Mannheim, Germany) as a Substrate. The 
method is outlined in detail by the manufacturer (Boehringer). 
The coagulation proteinases, plasma kallikrein and thrombin, were estimated by 
their cleavage activity on the chromogenic peptide Substrates S-2302 (Kabi, Stock-
holm, Sweden) and Chromozym TH (Boehringer, Mannheim, Germany), respective-
ly, after the turnover of the proenzymes to the active proteinases. 
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The inhibitory activities of antithrombin III and otjPI were measured with com-
mercially available test Systems (Coatest Antithrombin, Kabi, Stockholm, Sweden; 
-Antitrypsin Farbtest, Boehringer, Mannheim, Germany) applying chromogenic 
peptide Substrates for thrombin (S-2238) and trypsin (BAPA), respectively. The anti-
gen levels of the inhibitors were quantified with commercial radial immunodiffusion 
plates (Nor-Partigen plates, Behringwerke, Marburg, Germany). 
Opsonic activity, antigen levels, and split products of the Opsonins IgG and com-
plement factor C3 were determined as outlined in Billing et al. (1990, 1991) and 
Machleidt et al. (1991). 
An elastase-specific split product of the Aa-chain of fibrinogen, called fibrino-
elastase-peptide (FEP; equivalent to the Act 1-21 peptide described by Weitz et al. 
1986), was quantified with a two-step competitive immunoassay just recently devel-
oped in our laboratory (Gippner-Steppert 1991). 
Clinical methods, treatment of patients, and experimental therapeutic studies are 
extensively described in the original publications cited in the following sections. 
3 Results and Discussion 
3.1 Proteolysis-Induced Pathomechanisms i n H u m a n s 
3 . 1 . 1 M u l t i p l e T r a u m a 
In an extended exploration 100 severely injured patients fulfilling previously defined 
study criteria were enrolled in a prospective study (directed by Drs. Nast-Kolb and 
Waydhas, Surgical Clinic City, University of Munich) on inflammatory mediators 
and multiorgan failure (MOF) associated with polytraumatic events (Nast-Kolb et al. 
1990; Waydhas et al. 1991). Collection of blood samples and recording of clinical 
data were started within 30 minutes after arrival of the patients in the emergency 
department (about 1 h after the accident) and continued on a 6 h basis up to 48 h. 
Subsequently, the monitoring interval was extended to 24 h for a period of 14 days. 
Thereafter the clinical course was recorded until either transfer to a general ward or 
death of the patient. 
Retrospectively, the patients could be assigned to three different groups: 16 of 
them died due to MOF between 3 and 28 days (mean survival time: 16 days) after the 
traumatic incident (group I), 47 patients survived the development of organ failure 
(group II), and 37 patients recovered from the accident without evident signs of organ 
dysfunctions (group III). 
The extracellular release of PMN elastase and monocyte/macrophage-derived 
cathepsin B into plasma of the patients in the three outcome groups is depicted in Fig. 
2. PMN elastase was elevated in all groups significantly above normal (upper ränge 
120 ng/ml) already within 1 to 2 h after trauma and showed an additional increase up 
to the 12th posttraumatic hour. The differences between mean plasma levels in pa-
tients with (groups I and II) and without organ failure (group III) were highly signifi-
cant (p<0.01) throughout the whole Observation period. Moreover, patients dying 
due to organ failure (group I) and those who survived organ dysfunctions (group II) 
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were also significantly (p < 0.05) differentiated according to their mean PMN elastase 
plasma concentrations from the third posttraumatic day onwards. Cathepsin B plasma 
levels reached their maxima at least 6 h before complexed PMN elastase (Fig. 2). 
This early cathepsin B activity in circulating blood proved to be a sensitive and spe-
cific predictor of subsequent developing organ failure. Yet, it did not discriminate 
between lethal (group I) and reversible (group II) dysfunctions at that time. In con-
trast to PMN elastase, cathepsin B activity returned to only slightly elevated levels 
within 3 days in all patients (Fig. 2), thus not allowing a further differentiation of the 
three outcome groups. From these data the conclusion can be drawn, that the early 
release of lysosomal phagocyte proteinases after a severe traumatic event contributes 
to the occurrence of anticipated organ failure, and that at least the ongoing discharge 
of PMN elastase may be involved in the exacerbation of the clinical Situation. The 
latter seems to be confirmed by the appearance of the elastase-induced split product 
FEP of fibrinogen which is correlated to the continuous release of elastase and the 
development of lethal multiple organ failure as outlined in Fig. 3 for a severely inju-
red patient. 
Polytrauma-Patient 
(Plasma) 
2500 
ng Elastase/ml ng FEP/ml 
2000 * 
1500 
1000 
500 
500 
h 400 
300 
f- 200 
100 
0 
Elastase (ng/ml) - s - FEP (ng/ml) 
Fig. 3. Plasma levels of PMN elastase (in complex with GCj -proteinase Inhibitor) and fibrino-
elastase-peptide (FEP) in a polytraumatized patient with lethal multiple organ failure. Resp. F 
Respiratory failure; DIC disseminated intravascular coagulation; Ren. F. renal failure; ARDS 
acute respiratory distress Syndrome; Hep.F. hepatic failure 
Proteolysis-Induced Pathomechanisms in Acute Inflammation 79 
o 
in 
o 
c i n . . < 
o J_ 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
days Fig. 4. Mean values (± SEM) of antithrombin III inhibitory activity in plasma of multiply in-
jured patients assigned to three outcome groups. For further details, see Fig. 2 
Interestingly, the main clotting inhibitor, antithrombin III (AT III), showed a sig-
nificantly lower inhibitory activity (p < 0.01) in plasma of group I and II patients 
compared to group i n during the whole Observation period and in nonsurvivors 
(group I) compared to survivors with organ failure (group II) from the first posttrau-
matic week onwards (Fig. 4). Similar results were obtained concerning the rapid tur-
nover of the coagulation proenzyme, Prothrombin (data not shown) to thrombin, the 
essential target Proteinase of AT III. Thus, plasma levels of AT III and Prothrombin 
60% below normal in the early posttraurnatic phase were highly associated with the 
later appearance of severe organ dysfunctions, indicating that in addition to the re-
lease of lysosomal proteinases an overwhelming activation of the humoral proteolytic 
cascade Systems is also conducive to the perpetuation of the posttraurnatic in-
flammatory process. 
In another clinical study on multiply injured patients (Sturm 1991) we were espe-
cially interested in local proteolysis-induced mechanisms which might be involved in 
the pathogenesis of the most severe lung dysfunction, the acute respiratory distress 
Syndrome (ARDS). Daily drawn BALF (method described in Obertacke et al. 1991) 
samples allowed us to confirm a significantly increased local discharge of the phago-
cyte proteinases, elastase and cathepsin B, in subjects at high risk of developing 
ARDS (Jochum 1991). Although the (XjPI antigen levels in all BALF specimens of 
the traumatized patients were far above the normal values of healthy volunteers, these 
amounts were apparently insufficient in most cases to completely inhibit the PMN 
elastase released in the local epithelial milieu of the alveoli. Therefore, the obviously 
deficient inhibitory capacity of c^PI may have been caused by proteolytic and oxida-
tive denaturation as well. Applying special assay Systems, both ways of ctjPI destruc-
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Proteolytic Activity 
(BALF) 
2500 
2000 
1500 
1000 
500 -
ng/ml Elastase Rel.Fluorescence 
free Elastase Casein Prot.*a1PI ^ Casein Prot.-a1PI 
Fig. 5. Proteolytic activity (degradation of resorufin-casein with and without addition of <xr 
proteinase inhibitor) and free PMN elastase in serial broncho alveolar lavage fluids (BALF) of a 
severely traumatized patient. Acute respiratory distress Syndrome and multiple organ failure 
persisted from the 5th to 12th posttraurnatic day 
tion were demonstrated by Schraufstatter et al. (1984), at least in some individual 
BALF samples of patients with manifest ARDS. Although other researchers could not 
detect elastase activity against high molecular weight protein Substrates in BALF 
samples of ARDS patients (Idell et al. 1985; Wewers et al. 1988), we were recently 
able to show caseinolytic activity in a variety of BALF samples (kindly given to us by 
Dr. Obertacke, Surgical Clinic, University of Essen) from trauma patients with severe 
lung dysfunctions (Machleidt et al. 1991). In vitro incubation of these specimens with 
ocjPI abolished nearly completely this proteolytic activity (Fig. 5) and gave rise to an 
additional increase in the elastase-otjPI complex, indicating that the enzymatic activ-
ity present in the alveolar environment was mostly due to PMN elastase. 
Moreover, the destructive potency of elastase in vivo could be directly docu-
mented by the proof of augmented generation of FEP in close correlation to the rising 
amount of the extracellularly discharged PMN enzyme in BALF samples of patients 
with aggrevating respiratory failure (Fig. 6). Hence, the aggressive components of in-
flammatory cells, especially the lysosomal proteinases, may indeed contribute to the 
occurrence of lung dysfunction in severely traumatized patients. 
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Polytrauma-Patient 
(BALF) 
Elastase (gg/ml) FEP (ng/ml) 
12 i 1 300 
Elastase FEP 
Fig. 6. Total amount of PMN elastase (measured as complex with otj-proteinase inhibitor) and 
fibrino-elastase-peptide (FEP) in serial bronchoalveolar lavage fluids (BALF) of a severely 
traumatized patient with reversible respiratory dysfunction from the 2nd to the 7th posttrau-
rnatic day 
3.1.2 Sepsis and Peritonitis 
In several prospective clinical studies on patients suffering from bacterial infections 
after major surgical treatments, we could demonstrate an increasing release of PMN 
elastase into the circulation in accordance with the worsening of the inflammatory re-
action (Duswald et al. 1985; Inthorn and Jochum 1988; Jochum et al. 1990) Patients 
without postoperative infections showed only moderate, transiently elevated plasma 
levels of complexed elastase (up to three times that of normal) after Operation, where-
as onset and course of sepsis were characterized by markedly increased con-
centrations, up to 20-fold in individual cases. In patients with persisting septicemia, 
the elastase plasma levels remained significantly elevated until death, while a recov-
ery phase was accompanied by an obvious return to normal values. When complexed 
elastase increased in plasma, a prominent reduction of the humoral blood cascade 
proenzymes, prekallikrein and Prothrombin, as well as of the AT III inhibitory activ-
ity was measurable. This indicates that the proteolytic mechanisms in this pathologi-
cal Situation are quite similar to those seen in the course of developing posttraurnatic 
organ failure. In addition, we could demonstrate in some pilot measurements that 
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Sepsis-Patient 
(Plasma) 
2000 
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Elastase (ng/ml) 
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120 
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2/2 
Fig. 7. Plasma levels of PMN elastase (in complex with Otj -proteinase inhibitor) and fibrino-
elastase-peptide (FEP) of a patient with lethal outcome 2 days after diagnosis of sepsis due to 
bifurcation malacia of the trachea. 
during a septic shock phase, the monocyte/macrophage-derived cathepsin B was re-
leased in a manner similar to the PMN elastase, thus intensifying the extracellular 
proteolytic capacity. 
Just recently we were able to verify such a destructive proteolytic potency in a still 
ongoing prospective study (clinically directed by Dr. Inthorn, Surgical Clinic Groß-
hadern, University of Munich) on septic patients. To be enrolled in this investigation, 
patients had to fulfill all four previously defined septic criteria (septic focus and/or 
positive blood culture; body temperature > 38.5 ÄC; leukocytes > 15 000/|il or 
< 5000/|il; platelets < 100 000/^1 or drop of plarelets > 20% within 24 h), indicating a 
severe inflammatory Situation. Under these circumstances the generation of the elas-
tase-induced fibrinogen split product FEP was highly correlated to the plasma level of 
PMN elastase as shown in Fig. 7 for a patient who died 2 days after diagnosis of sep-
sis. Moreover, the unspecific proteolytic degradation of AT III, which is also highly 
susceptible to PMN elastase cleavage (Jochum et al. 1981; Jordan et al. 1989), could 
be determined by an indirect method comparing the amount of AT III antigen with its 
inhibitory activity as depicted in Fig. 8 for a patient suffering from eventually lethal 
sepsis. Besides the fact that AT III was already highly consumed throughout the 
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Fig. 8. Comparison of antithrombin III antigen (AT EI) levels (imm) and inhibitory activity 
(fct.) in plasma samples of a patient with lethal sepsis due to stomach Cancer. NP % of a norm 
plasma pool 
whole sepsis period of 8 days, the clearly lower inhibitory activity indicates that part 
of the in antigen level may be due either to complexes of the inhibitor with clotting 
enzymes or to proteolytically degraded molecules. Since the latter have an only 
slightly lower molecular weight and nearly the same half-life as the intact molecules 
(Jordan et al. 1989), they cannot be distinguished from the native AT III when quanti-
fied by radial immunodiffusion. In our patient, however, we could definitely rule out 
the possibility that AT Hl-proteinase complexes contributed significantly to the 
higher antigen levels, because due to the very Short half-life of only a few minutes, 
concentrations of AT III-thrombin complexes amounted to, at most, 0.01% of the 
overall AT III (data not shown in detail). Thus, elastase-inactivated AT III molecules 
should be present with high probability in the pathological Situation of severe sepsis. 
This assumption is further confirmed by results of Jordan et al. (1989) which demon-
strate that even catalytic amounts of heparin react with elastase in a way considerably 
accelerating the rate of AT III inactivation by this enzyme. Since heparin exists not 
only as a minor component on vascular endothelial cells, but is also used as a thera-
peutic drug in our patients, the positive regulation of hemostasis by heparin may be 
significantly counteracted by the adverse effect on AT III in the case of a high release 
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of elastase from PMN granulocytes adhering to the endothelial layer of the blood ves-
sel walls. 
Diffuse Peritonitis is often the source of a systemic spreading of local infectious 
complications, eventually leading to sepsis and multiorgan failure. In a previous work 
we were able to demonstrate that the impairment of opsonization in the peritoneal 
cavity allows the survival of huge numbers of bacteria despite the presence of intact 
phagocytes (Billing et al. 1988). Since the proteolytic breakdown of the main Op-
sonins IgG and complement factor C3 in Peritonitis exudates correlated well with the 
extracellularly released lysosomal proteinases elastase and cathepsin B in the local 
body fluids, we assumed that these enzymes are the principal causes of the deficiency 
in opsonic capacity. To assure this supposition, isolated IgG was incubated in vitro 
either with PMN elastase and cathepsin B or (in its isothiocyanate-labeled form = 
FITC IgG) with a cell-free, purulent Peritonitis exudate (kindly supplied by Dr. Bil-
ling, Surgical Clinic Großhadern, University of Munich). The proteolytic degradation 
was followed by gel chromatography of the split products exhibiting the same type of 
IgG cleavage pattern under all conditions (Billing et al. 1991; Machleidt et al. 1991). 
Using resorufin-labeled casein as a Substrate, similar results were obtained substan-
tiating proteolytic elastase activity despite the presence of an up to 40-fold molar sur-
Peritonitis-Patient 
(Exudate) 
50 
40 
30 
20 
10 
Elastase (ug/ml) FEP (ng/ml) 
preL. postL. 1h 2h 
500 
400 
300 
200 
-I 100 
8h 
Elastase FEP 
Fig. 9. PMN elastase (in complex with arproteinase inhibitor) and fibrino-elastase-peptide 
(FEP) in exudate samples taken before (preL) and immediately after (postL.) lavage of the ab-
domen of a Peritonitis patient with Ringer lactate Solution and in drainage fluids collected be-
tween 0 to 1 h, 1 to 2, and 2 to 8 h after lavage 
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plus of 04PI antigen in Peritonitis exudates (data not shown) as already discussed for 
BALF samples in trauma patients. In addition to the in vivo degradation of IgG and 
C3, we have successfully proved the generation of FEP in Peritonitis exudates just re-
cently. As depicted in Fig. 9, high amounts of complexed PMN elastase coincided 
with highly elevated FEP in the specimen drawn before surgical treatment of the ab-
domen of a patient with severe Peritonitis. After rinsing the peritoneal cavity with 101 
of Ringer lactate Solution both parameters decreased nearly to zero. Yet, as can be 
seen from the abdominal drainage fluids collected between 0 and 1, 1 and 2, and 2 
and 8 h after Operation, the release of PMN elastase started again, inducing also the 
production of FEP (Fig. 9). These observations may be taken as an indication of a still 
ongoing inflammatory reaction in this patient. 
Summarizing the data obtained in our clinical studies on patients suffering from 
multiple trauma and/or septicemia, we could clearly show that excessive local (a tPI) 
or systemic (AT III) consumption of Proteinase inhibitors concomitant to the release 
of lysosomal phagocyte proteinases and the activation of proteolytic blood cascade 
enzymes during severe inflammatory reactions is a most critical event which may 
contribute to the propagation of (multiple) organ damage. Therefore, supplementation 
of the body's inhibitor potential by exogenous Proteinase inhibitors - isolated from 
human material or produced by gene technology (Fritz et al. 1991) - seems to be a 
most promising therapeutic approach. 
32 Proteinase I n h i b i t i o n as a Suitable Therapeutic Approach 
i n Acute I n f l a m m a t i o n 
3.2.1 Inhibitors of PMN Elastase or Thrombin in Experimental Endotoxin Shock 
In a preliminary, controlled study on sepsis in young pigs the prophylactic application 
of the relatively specific recombinant elastase inhibitor, eglin c (originally isolated 
from the leech hirudo medicinalis), caused a significant reduction in the consumption 
of antithrombin III and other plasma proteins as well as in the formation of interstitial 
pulmonary edema (Jochum et al. 1987). As assessed by measurement of arterial blood 
pressure and total protein concentration in plasma, Siebeck et al. (1989a) demon-
strated in a more extended study that eglin c can also reduce the overall capillary 
leakage induced by the infusion of live E. coli in pigs. Moreover, in a further con-
trolled investigation, Siebeck et al. (1989b) and Hoffmann et al. (1990) could show 
that besides eglin c the thrombin-specific inhibitor hirudin - another recombinant in-
hibitor also formerly isolated from the medical leech - significantly improved endo-
toxin shock Syndromes in minipigs. Fibrinogen consumption, formation of fibrin 
monomers, the occurrence of pulmonary vasoconstriction, and the release of PMN 
constituents were clearly lower in endotoxemic animals treated with hirudin as com-
pared to those without continuous intravenous inhibitor infusion. Interestingly, the 
supplementation of a purified antithrombin III-heparin complex in another random-
ized porcine endotoxin shock model had only a slight, insignificant positive effect on 
the endotoxin-induced mortality and oxygen Saturation in arterial blood (as an indica-
tion of pulmonary function), although the consumption of fibrinogen and the forma-
tion of soluble fibrin monomers were clearly prevented in the drug-treated animals 
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(Spannagl et al. 1991). Furthermore, Prothrombin consumption was similar in the 
treatment and placebo groups, suggesting that local thrombin generation via factor Xa 
and binding of both enzymes to cell membrane receptors (e.g., thrombin to thrombo-
modulin) may protect them from inhibition by the AT III-heparin complex. On the 
other hand, the applied amount of the AT III-heparin complex may not have been suf-
ficient to inhibit the activation of contact phase enzymes (plasma kallikrein, factor 
Xlla) which are also supposed to be potent stimulators of PMN granulocytes (Wacht-
fogel et al. 1983; 1985), thus maintaining the inflammatory process via the release of 
phagocyte proteinases and reactive oxygen metabolites. Moreover, since after an ini-
tial rise (up to about 130%) the AT III activity decreased during further drug applica-
tion, while the antigen level still increased, the heparin in the complex may have also 
facilitated the inactivation of AT III by released PMN elastase (Jordan et al. 1989), 
thereby lowering the inhibitory capacity under an otherwise presumably effective 
threshold level. 
The requirement of high levels of AT III inhibitory activity in the circulation is 
also confirmed by results of Emerson et al. (1989) concerning the efficacy of an-
tithrombin III supplementation in several animal models (rat, sheep, baboon) of ful-
minant E. coli endotoxemia or bacteremia. Only very high dosage (up to threefold 
that of normal) and prophylactic administration of AT III prevented organ damage 
and increased permanent survival in the experimental animals. Interestingly, the com-
bined application of AT III and otjPI showed a significant synergistic improvement of 
the pulmonary function compared to the Single drug treatment in the endotoxemic 
sheep model. This indicates again that a complex interaction of lysosomal and hu-
moral blood cascade proteinases contribute to the perpetuation of a septic-like in-
flammation. 
3.2.2 Antithrombin III Supplementation in Clinical Sepsis 
From the therapeutic animal experiments and the apparent lack of sufficient efficacy 
of AT III supplementation in clinical studies (Blauhut et al. 1985; Vinazzer 1987), we 
draw the conclusion that only AT III levels well above the normal value may be able 
to improve organ dysfunctions in clinical sepsis. Therefore, we conducted a study 
(clinically directed by Dr. Inthorn, Surgical Clinic Großhadern) on septic patients 
with the aim to increase the AT III inhibitory activity above 120% that of normal. To 
achieve this, AT III concentrates were i.v. infused twice daily over 21 days according 
to a modified regimen originally described by Blauhut et al. (1985). Blood samples 
were taken twice daily throughout the whole Observation period. Preliminary data and 
a detailled outline of the Performance of the still ongoing study have been published 
(Jochum et al. 1991). Here, only the most important results will be presented. Up to 
now, 15 patients, each fulfilling the above-mentioned septic criteria, could be enrolled 
in the control and therapy groups. With our application scheme the AT III activity in 
the treatment group was elevated to mean plasma levels slightly below 120% during 
the first 9 days followed by an increase above 120% thereafter, whereas in the control 
group levels between 60% (early phase) and 80% (later phase) were measurable (Fig. 
10). Although all AT III-treated patient received nearly the same amount of the in-
hibitor concentrate (between 8000 and 4000 U/day), those individuals who survived 
the septic events showed clearly higher AT III levels (up to a mean of 135% during 
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Fig. 12. Mean values of PMN elastase (in complex with 04 -proteinase inhibitor) in plasma of 
survivors (n = 6) and nonsurvivors (n = 9) of the AT Iü-treatment group 
the first 5 days after sepsis diagnosis; Fig. 11) than patients who died despite AT III 
supplementation (mean AT III activity between 100% and 115% in the early septic 
phase). Thus, immediate AT III Substitution in sufficiently high amounts after early 
diagnosis of a septic episode appears to be of great importance in improving the sur-
vival of the patients. 
Probably due to a too late onset of the Inhibition therapy and the application of 
still insufficiently high AT III dosages in some of our patients, the Overall mortality 
could be reduced only from 87% in the control group to 60% in the AT III-treated 
collective. This diminution in lethality was statistically insignificant, yet a clear im-
provement of organ functions - especially lung, liver and kidney - in the treated pati-
ents as well as a further deterioration in the control group became evident. Mean 
plasma levels of complexed elastase were elevated up to sixfold that of normal upon 
admission and decreased gradually to about threefold in both groups until the end of 
the Observation period. Although there were no statistically significant differences, a 
slight trend to lower plasma elastase levels appeared in the AT III group. Similar mi-
nute distinctions were seen in AT III-treated patients who survived compared to those 
who died (Fig. 12). Plasma prekallikrein and Prothrombin levels were highly reduced 
up to 30 and 50%, respectively, upon admission and showed a more or less pronoun-
ced change to higher values (40 and 80% that of normal) later on without obvious dif-
ferences in the placebo and treatment groups. Interestingly, however, prekallikrein 
levels rose steadily up to 50% in AT III-treated survivors, whereas in the non-
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survivors a further transient decrease up to 20% occurred (Fig. 13). Comparable be-
havior was observed for Prothrombin which reached 80% of normal already 10 days 
after onset of sepsis in the AT ni-treated survivors, while in the moribund patients 
plasma Prothrombin levels as low as 60% were measured at that time. Thus, the rise 
in AT III inhibitory activity to nearly 140% in the early septic phase may have been 
beneficial enough to preserve clotting proenzymes from excessive activation through-
out a septic period. 
4 Conclusion 
The given data, derived from clinical and experimental studies on acute inflamma-
tion, unequivocally indicate that proteolytic pathomechanisms play an important role 
in the onset and perpetuation of inflammatory processes like trauma- and sepsis-in-
duced multiple organ dysfunctions. Therefore, the plasma levels of the regulatory 
Proteinase inhibitors have to be elevated by suitable supplementation and kept well 
above the normal values to achieve significant improvement of the clinical Situation. 
As the natural sources for the isolation of Proteinase inhibitors from human material 
are very limited, the design of highly effective inhibitory proteins, on the basis of 
human inhibitor molecules by molecular modeling and their production by recombi-
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nant DNA technology, is the most promising approach at present to obtain the quan-
tities necessary for Proteinase inhibition therapy in the future (Fritz et al. 1991). 
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